The Next Twilight Collection Is Here: Scentbird and Lionsgate Launch Exclusive The Twilight Saga: New Moon Fragrance

Scentbird will launch its exclusive, limited-edition The Twilight Saga: New Moon Eau de Parfum on October 1, 2026, following what it describes as a top-selling debut Twilight fragrance SKU. The product will be sold exclusively through Scentbird from $4.95 for a sample to $90 for a 50ml bottle, supported by fan activations and cast-led creator marketing. The collaboration extends Lionsgate's Twilight franchise monetization into consumer products, but no revenue, sales, or financial guidance was disclosed.

Analysis

This is directionally positive for LION’s licensing flywheel, but immaterial to consolidated earnings: a niche, exclusive DTC product can generate high-margin royalty revenue and valuable first-party fandom data without Lionsgate carrying inventory or marketing risk. The more important read-through is validation that dormant catalog IP can be monetized ahead of the Netflix adaptation cycle, potentially supporting licensing renewals and broader consumer-products attach rates rather than moving near-term studio EBITDA.

The 1-3 month catalyst is sell-through evidence and whether the campaign converts into recurring subscription acquisition for Scentbird; neither metric is disclosed, so the company’s “top-selling” characterization is not independently investable. If the launch sells through rapidly, LION could extend the fragrance format across additional franchise chapters or use the adaptation’s publicity window for higher-value retail, games, and experiential partnerships. NFLX benefits only indirectly: the product broadens franchise awareness, but it does not alter Netflix economics absent evidence that the forthcoming series drives meaningful subscriber engagement.

Consensus may overvalue headline licensing announcements while missing the reverse risk: nostalgia licensing can exhaust a finite fan base if releases proliferate before new screen content refreshes demand. For LION, the relevant falsifier is not fragrance sales but a failure to convert IP activity into reported licensing revenue growth and improved segment contribution over the next two earnings reports; standalone limited-edition launches should not command a multiple re-rating.

Key Decisions for Investors

• No standalone trade on this release; the likely royalty pool is too small versus LION’s enterprise value and there is no disclosed unit volume, royalty rate, or minimum guarantee.
• Maintain LION on a 6-12 month watchlist for a long catalyst around Netflix-series marketing and licensing disclosures; upgrade only if management demonstrates sustained licensing/consumer-products growth in the next two quarterly reports. Exit a thesis position on weaker licensing guidance or delayed series timing.
• Do not buy NFLX on the franchise-merchandise read-through. Treat measurable series engagement after release—not pre-launch consumer collaborations—as the trigger for any content-driven Netflix view.
• Monitor FNKO and RBLX only for follow-on Twilight licensing announcements; a multi-category consumer-product or platform integration would be a stronger signal of franchise reactivation than this limited DTC launch.